Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study [0.03%]
卡那奴单抗治疗sJIA、FMF、TRAPS和MKD/HIDS的临床模式：来自比利时非干预性研究的实际见解
Michel Moutschen,Cécile Boulanger,Joke Dehoorne et al.
Michel Moutschen et al.
Background: Canakinumab, an IL-1β inhibitor, has demonstrated long-term efficacy and safety in patients with sJIA, FMF, TRAPS, and MKD/HIDS who experience inadequate disease control with conventional treatments. This non...
Canakinumab for the treatment of postprandial hypoglycaemia: study protocol for a randomised, placebo-controlled, parallel-group, double-blind, multicentric, superiority trial-the CanpHy study [0.03%]
卡那奴单抗治疗餐后低血糖症：随机、双盲、安慰剂对照的平行分组非劣效性临床试验方案——CanpHy研究
Matthias Hepprich,Justus Fischer,Marco Cattaneo et al.
Matthias Hepprich et al.
Introduction: Postbariatric hypoglycaemia (PBH) is a complex medical condition with a significant impact on patients' quality of life. The underlying mechanisms remain to be elucidated. We have shown that food ingestion i...
Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system [0.03%]
基于美国食品药品监督管理局不良事件报告系统的托法替布药物上市后再评价研究：真实世界药物流行病学分析
Hao Liu,Wei Yan,Jinsong Li et al.
Hao Liu et al.
Background: Anakinra and canakinumab are two FDA-approved IL-1 blockers indicated for the treatment of multiple autoinflammatory diseases, yet their safety has not been comprehensively analyzed. We aimed to assess the saf...
Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review [0.03%]
卡那奴单抗治疗坏死性瘭疽样脓皮病2例报告及文献复习
Howard Jie Yang,William Spratt,Francis Yi Xing Lai et al.
Howard Jie Yang et al.
Aims: To evaluate the efficacy and adverse events of canakinumab in the treatment of pyoderma gangrenosum (PG). Methods: We report two ...
Buzzing Away Pain: Efficacy of Buzzy® in Reducing Pain During Canakinumab Treatment for Familial Mediterranean Fever [0.03%]
利用Buzzy减轻疼痛感在治疗地中海发热卡那单抗过程中的有效性研究
Nebahat Zeynep Özaslan,Betül Öksel,Nihal Sahin et al.
Nebahat Zeynep Özaslan et al.
Background: In colchicine-resistant patients with familial Mediterranean fever (FMF), alternative therapies, which are administered parenterally, become necessary. Effective pain management is essential for FMF treatment....
The Efficacy and Safety of Hepatitis A Vaccine in Children and Young Adults With an Autoinflammatory Diseases on Canakinumab and Tocilizumab Treatments: A Prospective Observational Controlled Study [0.03%]
针对接受卡那奴单抗和托珠单抗治疗的自身炎症性疾病儿童及青年患者的甲型肝炎疫苗有效性和安全性：一项前瞻性对照观察研究
Kenan Barut,Mehmet Yildiz,Ömer Faruk Beşer et al.
Kenan Barut et al.
Intro: In this prospective interventional study, we aimed to assess the efficacy and safety of the hepatitis A vaccine in patients with autoinflammatory diseases undergoing canakinumab and tocilizumab treatments. ...
Observational Study
International journal of rheumatic diseases. 2025 Apr;28(4):e70196. DOI:10.1111/1756-185X.70196 2025
The effect of IL-1β inhibitor canakinumab (Ilaris®) on IL-6 production in human skeletal muscle cells [0.03%]
IL-1β抑制剂Canakinumab（Ilaris®）对人骨骼肌细胞中IL-6生成的影响
Anna Cordeiro-Santanach,Fiorella Morales,Maria Del Carmen Parquet et al.
Anna Cordeiro-Santanach et al.
Muscle inflammation is one of the hallmarks of Duchenne muscular dystrophy (DMD). Dystrophin-deficient skeletal muscle cells produce higher levels of pro-inflammatory cytokines such as interleukin 1β (IL-1β) in response to toll-like recep...
Successful control of recurrent MAS by canakinumab in a Sjogren syndrome patient with homozygous MEFV P369S variants, and review of literatures [0.03%]
MEFV基因P369S纯合突变的原发干燥综合征患者成功应用卡那奴单抗治疗复发性周期性发热-皮肤粘膜炎-血小板减少综合征一例及文献复习
Nobuyuki Ono,Motoki Yoshimura,Toshiya Nishida et al.
Nobuyuki Ono et al.
Macrophage activation syndrome (MAS) is an autoinflammatory condition, which severely complicates autoimmune diseases, such as SJIA, AOSD and SLE. MEFV gene encodes a component of Pyrin inflammasome, whose variants cause familial Mediterran...
Canakinumab Treatment in Familial Mediterranean Fever Patients: With/Without Colchicine [0.03%]
卡那奴单抗治疗家族性地中海热患者的效果研究：有或无秋水仙碱的使用
Tahir Saygın Öğüt,Veli Yazisiz,Melis Dilbil et al.
Tahir Saygın Öğüt et al.
Objectives: To compare the differences in attack characteristics, acute-phase reactants, and renal outcomes in patients using canakinumab with or without colchicine treatment. ...
Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) [0.03%]
FDA不良事件报告系统中卡那单抗上市后药物警戒研究
Weidong Zhang,Yunzhou Chen,Zeyu Yao et al.
Weidong Zhang et al.
Background: Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential. Thus, we comprehensively evaluated the ...
耗时 0.09246 秒，为您在
48206918
条记录里面共找到 333 篇文章 [XML]